The upside potential for NLNK just got a whole lot more interesting. the other week awesom_sto-cks alerted this company i think. google them .
I think NLNK might have reached its upward limit and that a pullback may be possible. check out https://hotstocks123.blogspot.com, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
NLNK may be a compelling opportunity. I started receiving notifications from Awe-Some.Sto-ck.s the other week and so far they have presented interesting new trade ideas.
Waiting for this awesome correction to occur. Don't get too nervous and sell yourself short. A lot of people made that mistake with INO while I was doubling down at 5.38 last month and just reaped the rewards today.
notable option activity just reported for NLNK on TS platform
When everyone wakes up this baby will be in $20......Confusion is about "missing patients" but that was already disclosed go back and read their data. Harold needs to get another hobby stop bashing the stock and look at the facts
Below my comment to the SA article of a few days ago that triggered the big PPS decline. An oncologist would find this article ridicolous, but I guess most investors are not expert of such matters and easily manipulated and their shares stolen. https://seekingalpha.com/article/4106042-newlink-curious-case-missing-patients QUOTE 'The how and why is straightforward. This is a trial in advanced melanoma. Patients have visible tumors on their skin and have seen their disease progress to an advanced stage. These patients and their doctors can observe when their skin lesions shrink or grow and can quickly make decisions on whether to stay on trial or try other treatments' You do not know what you are talking about. Melanoma advanced disease has internal metastases which spread through lympathic or blood vessels and need a CT or MRI to be evaluated/detected. The primary tumor (on the skin) is always excised much earlier and usually before it gets to an advanced stage. The evalued patients were the 60 evaluable patients as of Jan 2017 cut off. This was simply an update on those patients. Moreover ocular melanoma is usually refractory to CI, so it is correct to extract the cutaneous melanoma data and make them comparable to the INCY and other pembrolizumab/nivolumab monotherapy or combination trials. To the doctors or the ones who are expert of melanoma, this article you wrote is laughable. UNQUOTE
Newlink And The Curious Case Of The Missing Patients
Newlink’s Phase 2 data for indoximod and Keytruda for advanced melanoma have serious flaws. The trial “results” excluded nearly 50% of enrolled patients, which
Piece of trash after run. Sold
This scam is still 2x up for nothing! Has to fall below $5.00. Huge room to fall.
Soon back to $5.00
$1.00 stock, huge room to fall.
Here we go....big rise today!
Next step 15.5$ .... add there and wait till +20$ again! GLTA
#Harold, how many chat room are you in? I saw you on at least 3 of them bashing stocks.